天津医药

• 论著 •    

塞来昔布对人胃癌SGC-7901细胞迁移、MMP-9和VEGF表达的影响

魏永新1,张志广2,李熳2,钟江明3   

  1. 1. 天津医科大学研究生院
    2. 天津医科大学第二医院消化科
    3. 福建省立医院
  • 收稿日期:2013-01-24 修回日期:2013-05-09 出版日期:2013-10-15 发布日期:2013-10-15
  • 通讯作者: 魏永新

Effects of Celecoxib on the Cell Migration, MMP-9and VEGF Expression in Human Gastric Cancer SGC-7901

WEI Yong xin1,ZHANG Zhi guang2,LI Man 2,ZHONG Jiang ming3   

  1. 1. Graduate School of Tianjin Medical University
    2. Department of Gastroenterology,The Second Hospital of Tianjin Medical University
    3. Fujian Provincial Hospital
  • Received:2013-01-24 Revised:2013-05-09 Published:2013-10-15 Online:2013-10-15
  • Contact: WEI Yong xin

PDF (PC)

2206

摘要：

【摘要】 目的  观察塞来昔布对人胃癌SGC-7901细胞迁移能力及其对MMP-9mRNA和VEGF mRNA表达的影响。  方法  体外培养胃癌SGC-7901细胞，将细胞分为对照组及塞来昔布低、中、高剂量组（分别加入塞来昔布25、50、100μmol/L），处理SGC-7901细胞24h后，应用损伤修复实验观察塞来昔布对SGC-7901细胞迁移能力的影响；RT-PCR法检测塞来昔布对SGC-7901细胞MMP-9mRNA和VEGF mRNA表达的影响。  结果  SGC-7901细胞的迁移距离随塞来昔布浓度的增加而减少，中、高剂量组与对照组比较差异有统计学意义（322.33±0.75、245.51±0.58vs713.23±0.44，P＜0.05）。RT-PCR法检测结果显示，随着塞来昔布处理浓度的增高，胃癌细胞MMP-9mRNA和VEGFmRNA的表达均降低，且与对照组比较差异有统计学意义（P＜0.05）。  结论  塞来昔布可抑制人胃癌SGC-7901细胞的迁移，其抗肿瘤机制可能与抑制COX-2下游的MMP-9和VEGF表达有关。

关键词: 胃肿瘤, 前列腺素内过氧化物合酶类, 基质金属蛋白酶9, 血管内皮生长因子类, 塞来昔布

Abstract:

[Abstract]   Objective   To observe selective cyclooxygenase-2(COX-2) inhibitor celecoxib on the cell migration,
MMP-9and VEGF expression of human gastric cancer SGC-7901.   Methods   In vitro culture of SGC-7901cells, the cells were divided into blank control group and celecoxib treatment group (different concentrations of celecoxib25, 50and 100μmol/L). SGC-7901cells were treated with celecoxib for24h. The effect of celecoxib on cell migration of SGC-7901 was detected by the damage repair experiment. RT-PCR assay was used to detect the effect of celecoxib on MMP-9mRNA and VEGF mRNA expressions in SGC-7901cells.  Results   The migration distance of SGC-7901cells was decreased with the increased concentration of celecoxib. There were significant differences between medium-dose and high-dose celecoxib groups and the control group. RT-PCR assay showed that MMP-9mRNA and VEGF mRNA expressions in gastric cancer SGC-7901were significantly decreased with the increased concentration of celecoxib, and there was a significant difference compared with those of control group  (P<0.05).  Conclusion   Celecoxib can inhibit migration of human gastric cancer SGC-7901cells, which may be related to the inhibition of COX-2downstream of MMP-9and VEGF expressions.

Key words: stomach neoplasms, prostaglandin-endoperoxide synthases, matrix metalloproteinase9, vascular endothelial growth factors, celecoxib